{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:24:26Z","timestamp":1773833066696,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T00:00:00Z","timestamp":1519171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/pr.2018.11","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T17:01:05Z","timestamp":1516726865000},"page":"1041-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat"],"prefix":"10.1038","volume":"83","author":[{"given":"Jiro","family":"Kino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kitao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Akagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohsaku","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Kimata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,21]]},"reference":[{"key":"BFpr201811_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","volume":"362","author":"AA Eddy","year":"2003","unstructured":"Eddy AA, Symons JM . Nephrotic syndrome in childhood. Lancet 2003;362:629\u201339.","journal-title":"Lancet"},{"key":"BFpr201811_CR2","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/kisup.2012.16","volume":"2","author":"KDIGO","year":"2012","unstructured":"KDIGO. Chapter 3: steroid-sensitive nephrotic syndrome in children. Kidney Int Suppl 2012;2:163\u201371.","journal-title":"Kidney Int Suppl"},{"key":"BFpr201811_CR3","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1172\/JCI20402","volume":"113","author":"J Reiser","year":"2004","unstructured":"Reiser J, von Gersdorff G, Loos M et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004;113:1390\u20137.","journal-title":"J Clin Invest"},{"key":"BFpr201811_CR4","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood-2009-11-251132","volume":"115","author":"V Audard","year":"2010","unstructured":"Audard V, Zhang SY, Copie-Bergman C et al. Occurrence of minimal change nephrotic syndrome in classical Hodgkin lymphoma is closely related to the induction of c-mip in Hodgkin-Reed Sternberg cells and podocytes. Blood 2010;115:3756\u201362.","journal-title":"Blood"},{"key":"BFpr201811_CR5","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00467-016-3379-4","volume":"31","author":"G Cara-Fuentes","year":"2016","unstructured":"Cara-Fuentes G, Clapp WL, Johnson RJ, Garin EH . Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms. Pediatr Nephrol 2016;31:2179\u201389.","journal-title":"Pediatr Nephrol"},{"key":"BFpr201811_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1093\/ckj\/sfs001","volume":"5","author":"M Barton","year":"2012","unstructured":"Barton M, Tharaux PL . Endothelin and the podocyte. Clin Kidney J 2012;5:17\u201327.","journal-title":"Clin Kidney J"},{"key":"BFpr201811_CR7","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1476-5381.2012.02070.x","volume":"167","author":"N Dhaun","year":"2012","unstructured":"Dhaun N, Webb DJ, Kluth DC . Endothelin-1 and the kidney\u2013beyond BP. Br J Pharmacol 2012;167:720\u201331.","journal-title":"Br J Pharmacol"},{"key":"BFpr201811_CR8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1681\/ASN.2013020195","volume":"25","author":"O Lenoir","year":"2014","unstructured":"Lenoir O, Milon M, Virsolvy A et al. Direct action of Endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 2014;25:1050\u201362.","journal-title":"J Am Soc Nephrol"},{"key":"BFpr201811_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/ndt\/12.5.1001","volume":"12","author":"I Ebihara","year":"1997","unstructured":"Ebihara I, Nakamura T, Tomino Y, Koide H . Effect of a specific endothelin receptor A antagonist and an angiotensin converting enzyme inhibitor on glomerular mRNA levels for extracellular matrix components, metalloproteinases (MMP) and a tissue inhibitor of MMP in aminonucleoside nephrosis. Nephrol Dial Transplant 1997;12:1001\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"BFpr201811_CR10","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1161\/01.HYP.0000149249.09147.b4","volume":"44","author":"J Ortmann","year":"2004","unstructured":"Ortmann J, Amann K, Brandes RP et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004;44:974\u201381.","journal-title":"Hypertension"},{"key":"BFpr201811_CR11","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1681\/ASN.2008050482","volume":"20","author":"RR Wenzel","year":"2009","unstructured":"Wenzel RR, Littke T, Kuranoff S et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"BFpr201811_CR12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411\u20135.","journal-title":"Nature"},{"key":"BFpr201811_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1096\/fasebj.3.9.2545495","volume":"3","author":"RF Furchgott","year":"1989","unstructured":"Furchgott RF, Vanhoutte PM . Endothelium-derived relaxing and contracting factors. FASEB J 1989;3:2007\u201318.","journal-title":"FASEB J"},{"key":"BFpr201811_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1172\/JCI115822","volume":"90","author":"Y Terada","year":"1992","unstructured":"Terada Y, Tomita K, Nonoguchi H, Marumo F . Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J Clin Invest 1992;90:107\u201312.","journal-title":"J Clin Invest"},{"key":"BFpr201811_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00060.2009","volume":"91","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Rossi NF, Inscho EW, Pollock DM . Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011;91:1\u201377.","journal-title":"Physiol Rev"},{"key":"BFpr201811_CR16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/cphy.c100039","volume":"2","author":"DE Kohan","year":"2011","unstructured":"Kohan DE, Inscho EW, Wesson D, Pollock DM . Physiology of endothelin and the kidney. Compr Physiol 2011;2:883\u2013919.","journal-title":"Compr Physiol"},{"key":"BFpr201811_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/MNH.0000000000000185","volume":"25","author":"C De Miguel","year":"2016","unstructured":"De Miguel C, Speed JS, Kasztan M, Gohar EY, Pollock DM . Endothelin-1 and the kidney: new perspectives and recent findings. Curr Opin Nephrol Hypertens 2016;25:35\u201341.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFpr201811_CR18","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3181\/00379727-231-2310840","volume":"231","author":"S Sauvageau","year":"2006","unstructured":"Sauvageau S, Thorin E, Caron A, Dupuis J . Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Exp Biol Med 2006;231:840\u20136.","journal-title":"Exp Biol Med"},{"key":"BFpr201811_CR19","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ahj.2009.11.028","volume":"159","author":"A Macchia","year":"2010","unstructured":"Macchia A, Marchioli R, Tognoni G et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 2010;159:245\u201357.","journal-title":"Am Heart J"},{"key":"BFpr201811_CR20","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010\u20139.","journal-title":"Circulation"},{"key":"BFpr201811_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/00005344-199424050-00005","volume":"24","author":"H Eid","year":"1994","unstructured":"Eid H, de Bold ML, Chen JH, de Bold AJ . Epicardial mesothelial cells synthesize and release endothelin. J Cardiovasc Pharmacol 1994;24:715\u201320.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFpr201811_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0272-6386(97)90004-4","volume":"29","author":"DE Kohan","year":"1997","unstructured":"Kohan DE . Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997;29:2\u201326.","journal-title":"Am J Kidney Dis"},{"key":"BFpr201811_CR23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1084\/jem.172.6.1741","volume":"172","author":"H Ehrenreich","year":"1990","unstructured":"Ehrenreich H, Anderson RW, Fox CH et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741\u20138.","journal-title":"J Exp Med"},{"key":"BFpr201811_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/08860220600778944","volume":"28","author":"A Drakopoulos","year":"2006","unstructured":"Drakopoulos A, Goumenos DS, Vlachojannis JG, Tsakas S . Endothelin receptors in the kidney of patients with proteinuric and non-proteinuric nephropathies. Ren Fail 2006;28:461\u20137.","journal-title":"Ren Fail"},{"key":"BFpr201811_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.kint.2016.02.018","volume":"90","author":"B Dufek","year":"2016","unstructured":"Dufek B, Meehan DT, Delimont D et al. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int 2016;90:300\u201310.","journal-title":"Kidney Int"},{"key":"BFpr201811_CR26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ncpneph0891","volume":"4","author":"M Barton","year":"2008","unstructured":"Barton M . Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008;4:490\u2013501.","journal-title":"Nat Clin Pract Nephrol"},{"key":"BFpr201811_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.bbadis.2010.03.012","volume":"1802","author":"M Barton","year":"2010","unstructured":"Barton M . Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010;1802:1203\u201313.","journal-title":"Biochim Biophys Acta"},{"key":"BFpr201811_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/ki.1991.38","volume":"39","author":"K Ohta","year":"1991","unstructured":"Ohta K, Hirata Y, Shichiri M et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307\u201311.","journal-title":"Kidney Int"},{"key":"BFpr201811_CR29","doi-asserted-by":"publisher","first-page":"e79963","DOI":"10.1371\/journal.pone.0079963","volume":"8","author":"RJ Tan","year":"2013","unstructured":"Tan RJ, Zhou L, Zhou D, Lin L, Liu Y . Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy. PLoS ONE 2013;8:e79963.","journal-title":"PLoS ONE"},{"key":"BFpr201811_CR30","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1159\/000072497","volume":"94","author":"M Ikebe","year":"2003","unstructured":"Ikebe M, Nonoguchi H, Nakayama Y et al. Regulation of endothelin-converting enzyme 1 in nephrotic syndrome in rats. Nephron Exp Nephrol 2003;94:e137\u201345.","journal-title":"Nephron Exp Nephrol"},{"key":"BFpr201811_CR31","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ki.2009.424","volume":"77","author":"P Mundel","year":"2010","unstructured":"Mundel P, Reiser J . Proteinuria: an enzymatic disease of the podocyte? Kidney Int 2010;77:571\u201380.","journal-title":"Kidney Int"},{"key":"BFpr201811_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ndt\/gfr271","volume":"27","author":"M Shimada","year":"2012","unstructured":"Shimada M, Ishimoto T, Lee PY et al. Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-\u03baB-dependent pathway. Nephrol Dial Transplant 2012;27:81\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"BFpr201811_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0167-5699(98)01418-2","volume":"20","author":"J Henry","year":"1999","unstructured":"Henry J, Miller MM, Pontarotti P . Structure and evolution of the extended B7 family. Immunol Today 1999;20:285\u20138.","journal-title":"Immunol Today"},{"key":"BFpr201811_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0955-0674(99)80027-1","volume":"11","author":"CA Chambers","year":"1999","unstructured":"Chambers CA, Allison JP . Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999;11:203\u201310.","journal-title":"Curr Opin Cell Biol"},{"key":"BFpr201811_CR35","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","volume":"369","author":"CC Yu","year":"2013","unstructured":"Yu CC, Fornoni A, Weins A et al. Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013;369:2416\u201323.","journal-title":"N Engl J Med"},{"key":"BFpr201811_CR36","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00467-017-3613-8","volume":"32","author":"OP Mishra","year":"2017","unstructured":"Mishra OP, Kumar R, Narayan G et al. Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome. Pediatr Nephrol 2017;32:1355\u201361.","journal-title":"Pediatr Nephrol"},{"key":"BFpr201811_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1159\/000348803","volume":"37","author":"T Shimo","year":"2013","unstructured":"Shimo T, Adachi Y, Yamanouchi S et al. A novel nuclear factor \u03baB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates puromycin aminonucleoside-induced nephrosis in mice. Am J Nephrol 2013;37:302\u20139.","journal-title":"Am J Nephrol"},{"key":"BFpr201811_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.semnephrol.2016.09.008","volume":"36","author":"P Mundel","year":"2016","unstructured":"Mundel P . Podocyte-targeted treatment for proteinuric kidney disease. Semin Nephrol 2016;36:459\u201362.","journal-title":"Semin Nephrol"},{"key":"BFpr201811_CR39","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1681\/ASN.2015091070","volume":"27","author":"M Garsen","year":"2016","unstructured":"Garsen M, Lenoir O, Rops AL et al. Endothelin-1 induces proteinuria by Heparanase-mediated disruption of the glomerular Glycocalyx. J Am Soc Nephrol 2016;27:3545\u201351.","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pr201811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr201811","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pr.2018.11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pr201811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T18:01:31Z","timestamp":1719770491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pr201811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,21]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFpr201811"],"URL":"https:\/\/doi.org\/10.1038\/pr.2018.11","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,21]]},"assertion":[{"value":"30 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}